The dramatic progress in deciphering the molecular architecture of acute myeloid leukaemia (AML) has led to the development of a new generation of targeted therapeutic agents, such as the multitargeted kinase inhibitor midostaurin, the isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib, and the B‐cell lymphoma (Bcl)‐2 and Hedgehog pathway inhibitors venetoclax and glasdegib, respectively, which recently received FDA approval.1, 2, 3, 4, 5. Here, BCL2 is linked to acute myeloid leukemia.